Welcome to our dedicated page for Novaccess Global news (Ticker: XSNX), a resource for investors and traders seeking the latest updates and insights on Novaccess Global stock.
NovAccess Global Inc (XSNX) is a clinical-stage biotech company pioneering novel immunotherapies for brain tumors and cancer diagnostics. This news hub provides investors and medical professionals with essential updates on therapeutic advancements, clinical trial progress, and strategic partnerships.
Our curated collection offers immediate access to verified press releases, regulatory filings, and scientific developments. Track milestones in their biomarker-driven platforms including IDH1-focused diagnostics and dendritic cell vaccine therapies. Key updates include:
• Clinical trial phases & regulatory submissions
• Intellectual property licensing agreements
• Research collaborations with medical institutions
• Peer-reviewed study publications
• Strategic business developments
Bookmark this page for real-time tracking of NovAccess Global's progress in developing precision immunotherapies for glioblastoma and other malignancies. All content is sourced directly from company disclosures and verified industry channels.
NovAccess Global (OTCQB:XSNX), a biomedical company, has filed a provisional patent with Cedars-Sinai for a new immunotherapy platform targeting brain tumors. The patent focuses on the IDH1 protein, which aids in cellular metabolism, predicting patient responses to treatments like glioblastoma. Research led by Dr. Chris Wheeler of StemVax, a NovAccess subsidiary, reveals IDH1's role in distinguishing long-term survivors post-vaccine therapy. This filing doubles the company's patent portfolio and aims to support the development of IDH1 and TLR-AD1, an FDA-designated Orphan Drug for malignant brain tumors. NovAccess plans to meet with the FDA to co-develop these technologies, hoping to improve treatment outcomes and life expectancy for brain cancer patients.
NovAccess Global Inc. (XSNX) has postponed its Annual Meeting of Shareholders scheduled for May 2024. The company plans to reschedule the meeting soon after announcing a virtual meeting for shareholders on May 6th, 2024.
NovAccess Global Inc. (OTCQB:XSNX) has obtained a new intellectual property license from Cedars-Sinai Medical Center to enhance its immunotherapy platform for central nervous system cancer patients. The license focuses on using Isocitrate Dehydrogenase-1 (IDH1) to predict patient responses to vaccine immunotherapy for malignant brain tumors like glioblastoma. This breakthrough research by Dr. Chris Wheeler aims to improve therapeutic strategies and patient outcomes for brain cancer treatment.
FAQ
What is the current stock price of Novaccess Global (XSNX)?
What is the market cap of Novaccess Global (XSNX)?
